Ai.gnosis

Divyansh Mangal and Raksheet Jain are Season 4's most academically sophisticated AI-for-good founders from Jaipur. Divyansh pursued advanced research in AI and quantum theory before co-founding Ai.gnosis: his trajectory from theoretical AI research to applied healthcare AI reflects the specific decision to prioritise social impact over academic prestige. As he explained during the pitch: his previous research had limited practical applications, and he wanted to create something that directly changed children's lives. Raksheet Jain, a BTech in Artificial Intelligence, built the technical architecture that converts clinical screening protocols (traditionally requiring trained psychologists, controlled environments, and hours of observation) into a 5-minute AI-powered digital assessment accessible from any smartphone. The engineering challenge was immense: autism screening is not a simple questionnaire but a complex behavioural analysis that requires interpreting subtle patterns in child

Ai.gnosis provides AI-powered autism screening that converts a 2 to 3 hour clinical assessment into a 5-minute digital screening at 86% lower cost (₹700 versus ₹5,000). The platform analyses behavioural patterns, developmental milestones, and communication markers using AI models trained on validated clinical datasets, generating a comprehensive screening report that identifies children who may be on the autism spectrum and recommends next steps. The non-invasive design principle is critical for parent adoption: the screening does not require clinical environments, medical equipment, or physical examination. Parents can complete it from home, reducing the stigma barrier (many Indian families avoid autism clinics due to social stigma) and the accessibility barrier (most specialist clinics are concentrated in metro cities).

Amount Asked: ₹50 lakhs Equity Offered: 4% Implied Pre-Money Valuation: ₹12.5 crore

Divyansh and Raksheet walked into Season 4 Episode 14 with the most medically urgent AI pitch of the season. They opened with the autism prevalence statistics that every parent fears: 1 in 100 children globally has ASD, India has an estimated 1.8 crore affected children, yet most remain undiagnosed because clinical screening is too expensive, too time-consuming, and too inaccessible. The founders highlighted the devastating consequences of delayed diagnosis: "In severe cases, parents refuse to acknowledge that their child may have a problem, which causes the diagnosis to be delayed. As a result, the child exhibits extreme anger, clumsy behaviour, and object tossing. Over time, this makes treatment much more difficult." This explanation of how denial plus inaccessible screening compounds into irreversible developmental delays was the pitch's most emotionally devastating disclosure.

Aman Gupta was the most vocally supportive Shark, declaring that the founders deserved a government award for addressing such a crucial societal issue. Peyush Bansal recognised the intersection of AI technology and healthcare accessibility that mirrors Lenskart's mission of making eye care accessible. Varun Dua (guest Shark, Acko CEO) saw the insurance and healthcare ecosystem integration potential. Vineeta Singh appreciated the mission but did not invest. Anupam Mittal did not invest despite acknowledging the social impact.

The founders asked ₹50 lakhs for 4% equity (₹12.5 crore valuation). Peyush, Aman, and Varun jointly offered ₹1 crore for 8% equity (₹12.5 crore valuation, same as the founders' implied valuation). The founders received DOUBLE their capital ask (₹1 crore versus ₹50 lakhs) at their exact implied valuation (₹12.5 crore), with twice the equity dilution (8% versus 4%). The deal gave the founders more capital than requested while maintaining their valuation, and brought three strategically diverse Sharks (consumer tech, healthcare platforms, insurance) into an AI healthcare startup.

Divyansh Mangal and Raksheet Jain accepted the three-Shark deal from Peyush Bansal, Aman Gupta, and Varun Dua at ₹1 crore for 8% equity, valuing Ai.gnosis at ₹12.5 crore. The deal brought the most healthcare-strategically diverse three-Shark combination of Season 4: consumer technology distribution (Aman, reaching millions of parents through boAt's consumer channels), healthcare platform scaling (Peyush, replicating Lenskart's healthcare accessibility model), and health insurance integration (Varun, potentially embedding autism screening into Acko's health insurance offerings).

Ai.gnosis continues building India's most accessible autism screening infrastructure post-Shark Tank. The platform is validated by Dr. S. Sitaraman, Vice Chancellor of the Indian College of Pediatrics, providing the highest possible institutional medical endorsement for an AI-powered screening tool. The 250 medical centre partnerships create a nationwide screening network that grows with each new paediatrician who adopts the platform. The three-Shark investment provides specific strategic pathways for scaling: Aman's boAt consumer channels could enable autism awareness campaigns reaching millions of parents, Peyush's Lenskart model of making specialised healthcare accessible through technology could be replicated for developmental screening, and Varun's Acko health insurance platform could embed Ai.gnosis screening as a covered benefit in insurance policies, making screening free for insured families.